Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
Abstract Objective Intra-tumoral heterogeneity of 18F‐fluorodeoxyglucose (18F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positi...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | Cancer Imaging |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40644-023-00608-0 |
| _version_ | 1797451720740044800 |
|---|---|
| author | Guang Ma Shuhui You Yizhao Xie Bingxin Gu Cheng Liu Xichun Hu Shaoli Song Biyun wang Zhongyi Yang |
| author_facet | Guang Ma Shuhui You Yizhao Xie Bingxin Gu Cheng Liu Xichun Hu Shaoli Song Biyun wang Zhongyi Yang |
| author_sort | Guang Ma |
| collection | DOAJ |
| description | Abstract Objective Intra-tumoral heterogeneity of 18F‐fluorodeoxyglucose (18F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positive breast cancer (MHBC) remains unknown. The aim of this study was to evaluate 18F‐FDG uptake heterogeneity to predict the treatment outcome of the dual target therapy with Trastuzumab and Pertuzumab(TP) in MHBC. Methods Thirty-two patients with MHBC who underwent 18F-FDG positron emission tomography/computed tomography (PET/CT) scan before TP were enrolled retrospectively. The region of interesting (ROI) of the lesions were drawn, and maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion glycolysis (TLG), metabolic tumor volume (MTV) and heterogeneity index (HI) were recorded. Correlation between PET/CT parameters and the treatment outcome was analyzed by Spearman Rank Test. The ability to predict prognosis were determined by time‐dependent survival receiver operating characteristic (ROC) analysis. And the survival analyses were then estimated by Kaplan‐Meier method and compared by log‐rank test. Results The survival analysis showed that HI50% calculated by delineating the lesion with 50%SUVmax as threshold was a significant predictor of patients with MHBC treated by the treatment with TP. Patients with HI50% (≥ 1.571) had a significantly worse prognosis of progression free survival (PFS) (6.87 vs. Not Reach, p = 0.001). The area under curve (AUC), the sensitivity and the specificity were 0.88, 100% and 63.6% for PFS, respectively. Conclusion 18F-FDG uptake heterogeneity may be useful for predicting the prognosis of MHBC patients treated by TP. |
| first_indexed | 2024-03-09T14:57:34Z |
| format | Article |
| id | doaj.art-e5a09c0e73834eac9ad0bdbae032ea73 |
| institution | Directory Open Access Journal |
| issn | 1470-7330 |
| language | English |
| last_indexed | 2024-03-09T14:57:34Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Imaging |
| spelling | doaj.art-e5a09c0e73834eac9ad0bdbae032ea732023-11-26T14:06:22ZengBMCCancer Imaging1470-73302023-09-012311810.1186/s40644-023-00608-0Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancerGuang Ma0Shuhui You1Yizhao Xie2Bingxin Gu3Cheng Liu4Xichun Hu5Shaoli Song6Biyun wang7Zhongyi Yang8Department of Nuclear Medicine, Fudan University Shanghai Cancer CenterDepartment of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer CenterDepartment of Medical Oncology, Zhongshan Hospital Fudan UniversityDepartment of Nuclear Medicine, Fudan University Shanghai Cancer CenterDepartment of Nuclear Medicine, Fudan University Shanghai Cancer CenterDepartment of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer CenterDepartment of Nuclear Medicine, Fudan University Shanghai Cancer CenterDepartment of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer CenterDepartment of Nuclear Medicine, Fudan University Shanghai Cancer CenterAbstract Objective Intra-tumoral heterogeneity of 18F‐fluorodeoxyglucose (18F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positive breast cancer (MHBC) remains unknown. The aim of this study was to evaluate 18F‐FDG uptake heterogeneity to predict the treatment outcome of the dual target therapy with Trastuzumab and Pertuzumab(TP) in MHBC. Methods Thirty-two patients with MHBC who underwent 18F-FDG positron emission tomography/computed tomography (PET/CT) scan before TP were enrolled retrospectively. The region of interesting (ROI) of the lesions were drawn, and maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion glycolysis (TLG), metabolic tumor volume (MTV) and heterogeneity index (HI) were recorded. Correlation between PET/CT parameters and the treatment outcome was analyzed by Spearman Rank Test. The ability to predict prognosis were determined by time‐dependent survival receiver operating characteristic (ROC) analysis. And the survival analyses were then estimated by Kaplan‐Meier method and compared by log‐rank test. Results The survival analysis showed that HI50% calculated by delineating the lesion with 50%SUVmax as threshold was a significant predictor of patients with MHBC treated by the treatment with TP. Patients with HI50% (≥ 1.571) had a significantly worse prognosis of progression free survival (PFS) (6.87 vs. Not Reach, p = 0.001). The area under curve (AUC), the sensitivity and the specificity were 0.88, 100% and 63.6% for PFS, respectively. Conclusion 18F-FDG uptake heterogeneity may be useful for predicting the prognosis of MHBC patients treated by TP.https://doi.org/10.1186/s40644-023-00608-0Heterogeneity of 18F-FDG uptakePrognosisMetastatic HER2 positive breast cancerDual target therapy |
| spellingShingle | Guang Ma Shuhui You Yizhao Xie Bingxin Gu Cheng Liu Xichun Hu Shaoli Song Biyun wang Zhongyi Yang Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer Cancer Imaging Heterogeneity of 18F-FDG uptake Prognosis Metastatic HER2 positive breast cancer Dual target therapy |
| title | Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer |
| title_full | Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer |
| title_fullStr | Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer |
| title_full_unstemmed | Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer |
| title_short | Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer |
| title_sort | pretreatment 18f fdg uptake heterogeneity may predict treatment outcome of combined trastuzumab and pertuzumab therapy in patients with metastatic her2 positive breast cancer |
| topic | Heterogeneity of 18F-FDG uptake Prognosis Metastatic HER2 positive breast cancer Dual target therapy |
| url | https://doi.org/10.1186/s40644-023-00608-0 |
| work_keys_str_mv | AT guangma pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer AT shuhuiyou pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer AT yizhaoxie pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer AT bingxingu pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer AT chengliu pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer AT xichunhu pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer AT shaolisong pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer AT biyunwang pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer AT zhongyiyang pretreatment18ffdguptakeheterogeneitymaypredicttreatmentoutcomeofcombinedtrastuzumabandpertuzumabtherapyinpatientswithmetastaticher2positivebreastcancer |